<DOC>
	<DOCNO>NCT00346957</DOCNO>
	<brief_summary>The purpose study determine concentration anecortave acetate ( 15 30 mg versus placebo ) safe effective inhibition growth blood vessel retina patient wet AMD .</brief_summary>
	<brief_title>A Phase II Study Anecortave Acetate Treatment Exudative Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Anecortave</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Ages 50 year Other protocoldefined inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>